• Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial 

      Luke, Jason J; Rutkowski, Piotr; Queirolo, Paola; Del Vecchio, Michele; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; de la Cruz Merino, Luis; Khattak, Muhammad A; Schadendorf, Dirk; Long, Georgina V; Ascierto, Paolo A; Mandala, Mario; De Galitiis, Federica; Haydon, Andrew; Dummer, Reinhard; Grob, Jean-Jacques; Robert, Caroline; Carlino, Matteo S; Mohr, Peter; Poklepovic, Andrew; Sondak, Vernon K; Scolyer, Richard A; Kirkwood, John M; Chen, Ke; Diede, Scott J; Ahsan, Sama; Ibrahim, Nageatte; Eggermont, Alexander M M; Investigators, KEYNOTE-716
      Published 2022
      Background Pembrolizumab prolongs progression-free and overall survival among patients with advanced melanoma and recurrence-free survival in resected stage III disease. KEYNOTE-716 assessed pembrolizumab as adjuvant ...
      Article